Inova Schar Cancer Institute Partners with N-of-One to Support the Launch of Inova’s Molecular Tumor Board

N-of-One’s Clinical Interpretation and Clinical Trial Matching Provides Patient-Specific Treatment Strategies to Empower Inova’s Precision Medicine Program

CONCORD, Mass.--()--N-of-One, Inc., a precision medicine oncology decision support company, today announced a partnership with Inova Schar Cancer Institute (ISCI) to support its molecular tumor board, the first in the DC metro area to invite patient and family participation. ISCI is an international center for advanced cancer care and research. Collaborating with clinical and scientific partners, ISCI conducts genomic and translational research to better understand, predict, prevent, and ultimately, eliminate cancer. As part of its contribution, N-of-One is providing patient-specific clinical interpretation and clinical trial matching for Inova’s in-house next generation sequencing (NGS) panels and re-interpretation with clinical trial matching of the test results from other commercial diagnostics labs.

N-of-One will provide Inova’s cancer specialists with the most relevant treatment options through the analysis of each patient’s unique molecular profile. This includes integrating multiple molecular tests and information from N-of-One’s proprietary database, which in turn, can help identify individualized treatment options.

Inova’s molecular tumor board is one of the few to include patients and their families in the board’s discussions. This allows patients to hear the discussion and be directly involved in determining the next steps in their cancer care. N-of-One interprets test results prior to the tumor board meeting, and during the meeting, senior scientists from Inova and N-of-One provide scientific support for questions on the test results and for the assessment of relevant treatment strategies. In addition to treatments, N-of-One can also provide clinical trial selection for patient cases. Currently there are hundreds of open clinical trials for targeted therapies.

“N-of-One’s patient-specific clinical analysis is a vital contribution to our tumor board review, and our precision medicine program in general. This collaboration is helping us realize better patient outcomes,” said Dr. Tim Cannon, Clinical Director, for the molecular tumor board and Precision Cancer Care Program. “This partnership empowers our oncologists to use molecular testing to find the best treatment available for their patients, including clinical trials.”

“ISCI has a robust precision medicine program, that includes both internal testing and outsourced testing,” said Chris Cournoyer, CEO of N-of-One. “We are pleased to provide Inova’s molecular tumor board with clinical interpretation and clinical trial matching, so that Inova cancer specialists and their patients can identify personalized treatment options.”

About Inova
Inova is a not-for-profit healthcare system based in Northern Virginia that serves more than 2 million people each year from throughout the Washington, DC, metro area and beyond. Inova is a comprehensive network of hospitals, outpatient services and facilities, primary and specialty care practices, and health and wellness initiatives.

Inova encompasses the full array of health services, including the area’s only Level 1 Trauma Center and Level IV neonatal intensive care unit (NICU). It is home to many nationally and internationally recognized programs, including Inova Heart and Vascular Institute (IHVI), Inova Translational Medicine Institute (ITMI), and the Inova Dwight and Martha Schar Cancer Institute.

Inova is a global leader in developing and applying personalized health. Connecting researchers, clinicians and empowered consumers, it integrates genomic research for patient care, prevention and wellness. Inova’s personalized health approach enables individuals to live longer, healthier lives.

More information and statistics about Inova are at www.inova.org.

About N-of-One
N-of-One is the leader in identifying patient-specific therapeutic options for precision medicine in oncology by leveraging its proprietary knowledgebase and its team of oncologists and Ph.D. scientists to integrate molecular data from multiple tests. Using N-of-One solutions can standardize and accelerate genomic clinical interpretation and molecular decision support while saving time and money. N-of-One’s solutions have provided therapeutic options, including clinical trials, for tens of thousands of patient cases across hundreds of cancer types. N-of-One partners with leading hospital systems, cancer centers, and commercial labs around the world. For more information, please visit www.n-of-one.com or call 617-202-9808.

Contacts

Feinstein Kean Healthcare
Lisa Rivero, 617-761-6780
lisa.rivero@fkhealth.com
or
Inova
Kelly Schlageter, 571-472-0200
kelly.schlageter@inova.org

Contacts

Feinstein Kean Healthcare
Lisa Rivero, 617-761-6780
lisa.rivero@fkhealth.com
or
Inova
Kelly Schlageter, 571-472-0200
kelly.schlageter@inova.org